Novartis plans to invest $23 billion over the next five years to expand its manufacturing and research in the U.S.
The investment will cover more than 10 facilities, including seven new sites, and will enable the drugmaker to produce its key medicines for the U.S. market, according to an April 10 news release from the company.
The plan includes building four new manufacturing facilities, two radiogland therapy production sites in Florida and Texas and a biomedical research hub in the San Diego area.
Existing sites in New Jersey, Indiana and California will be expanded, the release said. The investment is expected to create nearly 1,000 new jobs at Novartis and 4,000 additional jobs across the U.S.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
